Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery of Potent, Highly Selective, and In VivoEfficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing

Autor: Pissot Soldermann, Carole, Simic, Oliver, Renatus, Martin, Erbel, Paulus, Melkko, Samu, Wartmann, Markus, Bigaud, Marc, Weiss, Andreas, McSheehy, Paul, Endres, Ralf, Santos, Paulo, Blank, Jutta, Schuffenhauer, Ansgar, Bold, Guido, Buschmann, Nicole, Zoller, Thomas, Altmann, Eva, Manley, Paul W., Dix, Ina, Buchdunger, Elisabeth, Scesa, Julien, Quancard, Jean, Schlapbach, Achim, Bornancin, Frédéric, Radimerski, Thomas, Régnier, Catherine H.

Publikováno v: Journal of Medicinal Chemistry; December 2020, Vol. 63 Issue: 23 p14576-14593, 18p

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing.

Autor: Pissot Soldermann C; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Simic O; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Renatus M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Erbel P; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Melkko S; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Wartmann M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Bigaud M; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Weiss A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., McSheehy P; Basilea Pharmaceutica, CH-4002 Basel, Switzerland., Endres R, Santos P, Blank J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Schuffenhauer A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Bold G; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Buschmann N; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Zoller T; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Altmann E; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Manley PW; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Dix I; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Buchdunger E; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Scesa J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Quancard J; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Schlapbach A; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Bornancin F; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland., Radimerski T; Basilea Pharmaceutica, CH-4002 Basel, Switzerland., Régnier CH; Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Dec 10; Vol. 63 (23), pp. 14576-14593. Date of Electronic Publication: 2020 Nov 30.